J BUON [JOURNAL]
Sun
200 papers
Expression of Delta Like Ligand 4 (DLL4) in endometrial carcinomas and tumor vasculature.
Fasoulakis Z, Galazios G, Koukourakis M … +4 more , Nikolettos N, Giatromanolaki A, Koutlaki N, N Kontomanolis E
J BUON · 2021 · PMID 34564988
PURPOSE: Delta like ligand 4 (DLL4) is a transmembrane ligand of the Notch Signalling pathway, that regulates blood vessel sprouting and maturation. We investigated the expression of DLL4 in endometrial cancer. METHODS:...
PURPOSE: Delta like ligand 4 (DLL4) is a transmembrane ligand of the Notch Signalling pathway, that regulates blood vessel sprouting and maturation. We investigated the expression of DLL4 in endometrial cancer. METHODS: DLL4 was assessed in the plasma (with ELISA) and tissues (with immunohistochemistry) 33 patients with endometrial cancer, treated with radical hysterectomy for stage I endometroid carcinoma. The angiogenic activity (AA) of endometrial cancer was quantified by assessing the CD31+ microvessel density (MVD) in the invading tumor front. Vascular maturation index (VMI), defined as the percentage of CD31+ microvessels expressing DLL4, was calculated as the ratio of the CD31+ MVD to the DLL4+ MVD. RESULTS: The angiogenic activity was directly related with the histological grade (p=0.01). The VMI ranged from 0.1 to 0.7 (median 0.34). The concentration of DLL4 in the plasma ranged from 55-81pg/ml (mean 62.8) before, and dropped to 55-62 (mean 58.2) after hysterectomy (p<0.05). DLL4 was also expressed by cancer cells in 17/33 cases. No correlation between DLL4-related parameters with histopathological variables was noted. CONCLUSION: This pilot study shows that DLL4 is overexpressed in endometrial cancer cells, vasculature and is also elevated in the plasma of a fraction of patients before surgery. The percentage of DLL4+ vessels in the penetrating sample ranged from 10-70%, indicating a large difference in the quality of angiogenesis produced between the endometrial tumors of the same histological type and differentiation.
Curative effects of hysteroscopic resection combined with progesterone on early-stage endometrial cancer and its prognosis.
Kuang J, Sun S, Xu H … +2 more , Ni R, Ke F
J BUON · 2021 · PMID 34564987
PURPOSE: To explore the clinical efficacy of hysteroscopic resection combined with megestrol acetate in the treatment of patients with early-stage endometrial cancer (EC) and its prognosis. METHODS: 130 patients with ear...
PURPOSE: To explore the clinical efficacy of hysteroscopic resection combined with megestrol acetate in the treatment of patients with early-stage endometrial cancer (EC) and its prognosis. METHODS: 130 patients with early-stage EC were divided into two groups: MA group (hysteroscopic resection combined with megestrol acetate, n=65) and Control group (hysteroscopic resection alone, n=65). The clinical efficacy, serum carbohydrate antigen 125 (CA125) level and incidence of adverse reactions were compared between the two groups, and the patients' pregnancy status, pregnancy outcome, survival status and tumor recurrence were recorded through follow-up. RESULTS: The curative effect was assessed in all patients after treatment. The overall response rate was 83.1% (54/65) and 65.2% (43/65), respectively, in MA group and Control group, which was significant better in MA group than that in Control group. After treatment, the serum CA125 levels markedly declined in both groups. The pregnancy rate in MA group was obviously higher than in Control group. The follow-up results revealed that the 5-year overall survival (OS) was 83.1% (54/65) and 81.5% (53/65) and the progression-free survival (PFS) was 76.9% (50/65) and 73.8% (48/65), respectively, in MA group and Control group. CONCLUSION: Hysteroscopic resection combined with megestrol acetate has superior clinical efficacy to hysteroscopic resection alone in the treatment of patients with early-stage EC, which can greatly increase the success rate of pregnancy and reduce the serum CA125 level. However, thelong-term survival and PFS of patients had no significant differencesbetween the two treatment methods. Key words: hysteroscopic resection, megestrol acetate, endometrial cancer, early stage, curative effect.
Impact of combined mycoplasmataceae and HPV co-infection on females with cervical intraepithelial neoplasia and carcinoma.
Adamopoulou M, Avgoustidis D, Voyiatjaki C … +4 more , Beloukas A, Yapijakis C, Tsiambas E, Charvalos E
J BUON · 2021 · PMID 34564986
PURPOSE: The concurrent prevalence investigation of human papillomavirus (HPV), Mycoplasma hominis (Mh) and Ureaplasma urealyticum (Uu) in women in order to estimate the association of co-infection with cervical lesions....
PURPOSE: The concurrent prevalence investigation of human papillomavirus (HPV), Mycoplasma hominis (Mh) and Ureaplasma urealyticum (Uu) in women in order to estimate the association of co-infection with cervical lesions. METHODS: The study cohort comprised 120 women with no cervical lesions (control group) and 62 women with abnormal cytological findings from the cervix (cervical intraepithelial lesion/neoplasia) as study group. A combination of molecular analyses was implemented. RESULTS: The presence of HPV infection was shown in 52/62 (83.9%) of women with abnormal cytology. Women with cervix cytological findings were shown to have 17.6 times higher risk for Mh and Uu co-infection (p=0.001). HPV and Uu co-infection were detected with a higher prevalence among women with CIN 3 and invasive cancer. CONCLUSION: These findings are consistent with the notion that microbial co-infections may play an important role in persistent inflammation and progression of cervical lesions.
Neoadjuvant chemotherapy combined with laparoscopic cytoreductive surgery in patients with advanced ovarian cancer.
Wen A, Zhao L, Luo L … +2 more , Du C, Luo X
J BUON · 2021 · PMID 34564985
PURPOSE: To explore the clinical efficacy and safety of neoadjuvant chemotherapy (NACT) combined with minimally invasive laparoscopic cytoreductive surgery in the treatment of patients with advanced ovarian cancer (AOC)....
PURPOSE: To explore the clinical efficacy and safety of neoadjuvant chemotherapy (NACT) combined with minimally invasive laparoscopic cytoreductive surgery in the treatment of patients with advanced ovarian cancer (AOC). METHODS: The clinical data of 116 patients with AOC were divided into NACT group (NACT combined with laparoscopic cytoreductive surgery, n=58) and control group (cytoreductive surgery alone, n=58). The short-term efficacy, surgery-related indexes, incidence of adverse reactions, and changes in levels of serum human epididymis protein 4 (HE4), vascular endothelial growth factor (VEGF) and carbohydrate antigen 125 (CA125) before and after treatment were compared between the two groups. The survival status of patients after treatment was recorded. RESULTS: The operation time, intraoperative blood loss, ascites volume, postoperative ventilation time, and average postoperative length of hospitalization in NACT group were all significantly shorter and less than those in the control group. The optimal cytoreduction rate in NACT group was far higher than that in the control group. The overall response rate in NACT group was obviously higher than that in the control group. After treatment, the levels of serum HE4, VEGF and CA125 greatly declined in the two groups compared with those before treatment, while they were obviously lower in the NACT group than those in the control group. The follow-up results revealed that the median overall survival (OS) was 31.1 months and 28.9 months, and the 3-year OS rate was 43.1% (25/58) and 31.0% (18/58), respectively, in the NACT group and control group. CONCLUSION: NACT can significantly shorten the duration of cytoreductive surgery of AOC, reduce intraoperative blood loss, accelerate postoperative recovery, raise the optimal cytoreduction rate, and enhance the clinical efficacy, without greatly improving the survival of patients.
Efficacy of helical tomotherapy combined with CT-guided three-dimensional intracavitary brachytherapy in treatment of locally advanced cervical cancer.
Ye X, Ye P, Zheng Y … +1 more , Xia W
J BUON · 2021 · PMID 34564984
PURPOSE: We aimed to evaluate the efficacy and safety of helical tomotherapy (HT) combined with computed tomography (CT)-guided three-dimensional intracavitary brachytherapy (CT-ICBT) in the treatment of locally advanced...
PURPOSE: We aimed to evaluate the efficacy and safety of helical tomotherapy (HT) combined with computed tomography (CT)-guided three-dimensional intracavitary brachytherapy (CT-ICBT) in the treatment of locally advanced cervical cancer. METHODS: A total of 96 patients with locally advanced cervical cancer (IIB-IIIB) treated were retrospectively analyzed. They underwent concurrent radiochemotherapy, and the chemotherapy regimen paclitaxel + cisplatin was given for 3 weeks. The patients were divided into HT+CT-ICBT group (n=48) and intensity-modulated radiotherapy (IMRT) + two-dimensional ICBT (IMRT+ICBT group, n=48) according to the different extracorporeal and intracavitary radiotherapies. The short-term clinical efficacy, and short- and long-term adverse reactions were compared between the two groups, the tumor recurrence and survival status were recorded through follow-up, and the overall survival (OS) and progression-free survival (PFS) rates were compared between the two groups. RESULTS: The patient general clinical characteristics were comparable in both groups. The short-term clinical effective rate was 91.7% (44/48) and 87.5% (42/48), respectively, in HT+CT-ICBT group and IMRT+ICBT group. In the two groups, the incidence rate of grade 3-4 chronic radiation proctitis was 4.2% (2/48) and 22.9% (11/48), while that of grade 3-4 chronic radiation cystitis was 2.1% (1/48) and 18.7% (9/48), respectively. According to the follow-up results, the 3-year OS was 85.4% (41/48) and 77.1% (37/48), and the 3-year PFS was 81.3% (39/48) and 70.8% (34/48), respectively, in the two groups. Log-rank test showed that the 3-year OS and PFS had no statistically significant differences (p=0.395, p=0.401). CONCLUSION: HT+CT-ICBT is safe and effective in the treatment of locally advanced cervical cancer, and it has similar short-term clinical efficacy and long-term survival rate compared with IMRT+ICBT, which also significantly reduces the long-term incidence of radiation proctitis and cystitis, so it is worthy of popularization and application.
Development of a CAUTI risk factor evaluation index system for postoperative patients with gynecological malignant tumors.
Wang C, Shen X, Huang J … +2 more , Xia L, Wang H
J BUON · 2021 · PMID 34564983
PURPOSE: In this study, we developed a CAUTI risk factor evaluation index system for postoperative patients with gynecologic malignant tumors and provided scientific evidence for the prevention of catheter-related urinar...
PURPOSE: In this study, we developed a CAUTI risk factor evaluation index system for postoperative patients with gynecologic malignant tumors and provided scientific evidence for the prevention of catheter-related urinary tract infection (CAUTI). METHODS: A comprehensive method, including literature review, group discussion and Delphi method, was adopted to establish a CAUTI risk factor evaluation index system for postoperative patients with gynecologic malignant tumors. RESULTS: Two rounds of expert consultations resulted in effective response rates of 100%, with authority coefficients of 0.94, and coordination coefficients of 0.473 and 0.388 respectively (p<0.01). The risk factor indicator system consisted of 4 first-level indicators, 13 second-level indicators, and 56 third-level indicators. CONCLUSION: The experts showed high enthusiasm, good authority, and coordination. The CAUTI risk factor evaluation index system for postoperative patients with gynecologic malignant tumors is comprehensive and scientific, and could serve as an important guide for assessment and prevention of CAUTI in patients with gynecologic malignant tumor postoperatively.
FTO-stabilized lncRNA HOXC13-AS epigenetically upregulated FZD6 and activated Wnt/β-catenin signaling to drive cervical cancer proliferation, invasion, and EMT.
Wang T, Li W, Ye B … +3 more , Zhang S, Lei X, Zhang D
J BUON · 2021 · PMID 34564982
PURPOSE: Cervical cancer (CC) is the third most prevalent malignancy in women. Frizzled class receptor 6 (FZD6) is demonstrated to either activate or repress the activity of Wnt/β-catenin pathway, a crucial signaling inv...
PURPOSE: Cervical cancer (CC) is the third most prevalent malignancy in women. Frizzled class receptor 6 (FZD6) is demonstrated to either activate or repress the activity of Wnt/β-catenin pathway, a crucial signaling involved in cancer development. However, the role of FZD6 in CC is unknown. The present study explored the function of FZD6 and its mechanism in CC. METHODS: The levels of FZD6, HOXC13-AS were detected in CC specimens and CC cell lines via qRT-PCR. Cell proliferation and invasion was explored via CCK-8 assay, colony formation assay and transwell assay. Luciferase reporter analysis, FISH, subcellular fractionation, chromatin immunoprecipitation and RNA immunoprecipitation were performed for investigating the molecular mechanism. RESULTS: FZD6 was up-regulated in CC. FZD6 silence retarded proliferation, invasion, and epithelial-to-mesenchymal transition (EMT), and inactivated Wnt/β-catenin. HOXC13 antisense RNA (HOXC13-AS) was up-regulated in CC and positively correlated with FZD6. Mechanistically, HOCX13-AS1 augmented FZD through cAMP-response element binding protein-binding protein (CBP)-modulated histone H3 on lysine 27 acetylation (H3K27ac). Additionally, fat mass and obesity-associated protein (FTO) reduced N6-methyladenosine (m6A) and stabilized HOXC13-AS in CC. CONCLUSIONS: In conclusion, this study firstly showed that FTO-stabilized HOXC13-AS epigenetically up-regulated FZD6 and activated Wnt/β-catenin signaling to drive CC proliferation, invasion, and EMT, suggesting HOXC13-AS as a potential target for CC treatment.
Bevacizumab in recurrent ovarian cancer.
Sait Bakir M, Birge O, Karadag C … +4 more , Ilhan Y, Aykut Tuncer H, Sezgin Göksu S, Simsek T
J BUON · 2021 · PMID 34564981
PURPOSE: The cost-effectiveness of bevacizumab has been the subject of debate, and we aimed to present our own retrospective data on its effect on survival in recurrent epithelial ovarian cancer. METHODS: Patients with r...
PURPOSE: The cost-effectiveness of bevacizumab has been the subject of debate, and we aimed to present our own retrospective data on its effect on survival in recurrent epithelial ovarian cancer. METHODS: Patients with recurrent ovarian, tubal and primary peritoneal cancer between October 2007 and June 2018 were grouped according to the platinum-free interval. The progression-free and overall survivals of the patients who had received chemotherapy only and chemotherapy with bevacizumab were calculated. RESULTS: Eighty patients had received chemotherapy (CT) only, and 65 had received CT+BV. In platinum-sensitive recurrent epithelial ovarian cancer (PSREOC) patients, the median progression-free survival (PFS) months was 7 months (95% CI; 5.5-8.4) in the group who had received CT only and 13 months (95% CI; 5.8-20.1) in the group who had received CT+BV (p=0.001) and for CT+BV HR (Hazard Ratio):0.39 (95% CI; 0.24-0.64) (p=0.001). The median PFS of platinum-resistant recurrent epithelial ovarian cancer (PRREOC) patients who had received CT only was determined as 2 (95% CI; 1.4-2.5) and as 10 (95% CI; 6.8-13.1) months for patients who had received CT+BV (p=0.001), for patients who had received CT+BV HR: 0.31 (95% CI; 0.17-0.58) (p=0.001). In both PSREOC and PRREOC patients, there was no difference between CT + BV and CT group in terms of overall survival (p=0.978 and p=0.738, respectively). CONCLUSION: A significant effect of bevacizumab on the progression-free survival of both platinum-sensitive and platinum resistant recurrent ovarian cancers has been demonstrated; however, this effect failed to impact overall survival. Therefore, it could be recommended to use bevacizumab, considering the cost-effectiveness in undeveloped and developing countries.
Quality of life deterioration and colorectal cancer staging in elderly patients. Which comes first?
Diamantis A, Tzovaras G, Samara A … +5 more , Magouliotis D, Baloyiannis I, Symeonidis D, Arnaoutoglou E, Tepetes K
J BUON · 2021 · PMID 34564980
PURPOSE: Never before the preoperative quality of life (QoL) score of colorectal cancer (CRC) patients was analyzed and linked directly to cancer staging according to pathology in specimens and, thereafter, in patients t...
PURPOSE: Never before the preoperative quality of life (QoL) score of colorectal cancer (CRC) patients was analyzed and linked directly to cancer staging according to pathology in specimens and, thereafter, in patients to estimate long-term prognosis. Our study attempted to give answers to these questions. METHODS: This was a prospective study of 80 elderly patients who underwent major colorectal surgery for cancer in a single University's surgical department conducted between 01/2018 and 12/2018. All patients aged >65 years, diagnosed with a resectable CRC without metastatic disease undergoing an elective surgery were prospectively included. As exclusion criteria were considered age <65 years, an emergency operation, non-resectable tumor, stage IV CRC and American Society of Anesthesiologists (ASA) score IV. All patients were asked to answer a self-administered questionnaire of the validated Greek version of the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30. RESULTS: Comparison of the mean score of EORTC QLQ-C30 showed stage I CRC was 87.62% (11.81%), 77.24% (12.91%) in stage II patients and 78.99% (15.25%) in stage III cancer. The mean difference between the three groups was statistically significant (p=0.002). Moreover, in post-hoc analysis, there was a statistically significant difference in the mean QLQ-C30 score between patients with stage I and stage II cancer (p=0.043) and between patients with stage I and stage III tumor (p=0.01), but this difference was not observed when comparing patients with stage II and III cancer (p=0.319). CONCLUSION: Our study demonstrated a significant association between preoperative QoL and tumor staging as shown in the specimen's examination in elderly patients with CRC. More prospective studies are needed to elucidate how QoL and its fluctuations during the postoperative period can be correlated with long-term survival and disease progression in elderly CRC patients.
Mitomycin-C versus oxaliplatin during cytoreductive surgery and HIPEC for peritoneal metastases secondary to colorectal carcinoma: a retrospective analysis.
Spiliotis J, Kalles V, Prodromidou A … +4 more , Raptis A, Ferfelis M, Christopoulou A, Tsiatas M
J BUON · 2021 · PMID 34564979
PURPOSE: Combining cytoreductive surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) can benefit patients with peritoneal metastasis from colorectal cancer, however the optimal choice of the HIPEC chemot...
PURPOSE: Combining cytoreductive surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) can benefit patients with peritoneal metastasis from colorectal cancer, however the optimal choice of the HIPEC chemotherapy is still under debate. The present study compares the clinical outcome in patients with peritoneal metastases treated with CRS and HIPEC using Mitomycin - C versus Oxaliplatin. METHODS: We retrospectively analyzed patients that underwent CRS and HIPEC for recurrent colorectal cancer with peritoneal metastases. Patient characteristics, procedure details, and clinical outcomes were evaluated. RESULTS: 114 consecutive patients were included in the analysis (62 males - 52 females, mean age 58,3 years). The mean intraoperative PCI-score was 15.3 (range: 3 - 36). The mean follow-up period was 28.2 months. Patients receiving MMC - based HIPEC had significantly higher mean overall survival compared to oxaliplatin (54 versus 26 months), translated to a hazard ratio of 0.26 (95% CI 0.128 - 0.529, p<0.01). The HIPEC regimen as well as the completeness of cytoreduction were the only independent prognostic factors of survival in our sample. CONCLUSIONS: Our results imply that the use of MMC offers a survival advantage over oxaliplatin when used for HIPEC in CRC PC. A randomised trial comparing oxaliplatin and MMC would enhance decision-making in such patients.
Identification of sixteen metabolic genes as potential biomarkers for colon adenocarcinoma.
Zhao F, Liu Y, Gu X … +3 more , Zhang B, Song C, Cui B
J BUON · 2021 · PMID 34564978
PURPOSE: To identify some key prognosis-related metabolic genes (PRMG) and establish a clinical prognosis model for colon adenocarcinoma (COAD) patients. METHODS: We used The Cancer Genome Atlas (TCGA) and Gene Expressio...
PURPOSE: To identify some key prognosis-related metabolic genes (PRMG) and establish a clinical prognosis model for colon adenocarcinoma (COAD) patients. METHODS: We used The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) to obtain gene expression profiles of COAD, and then identified differentially expressed prognostic-related metabolic genes through R language and Perl software, Through univariate Cox analysis and least absolute shrinkage and selection operator (LASSO) Cox analysis to obtain target genes, established metabolic genes prognostic models and risk scores. Through Cox regression analysis, independent risk factors affecting the prognosis of COAD were analyzed, and receiver operating characteristics (ROC) curve analysis of independent prognostic factors was performed and a nomogram for predicting overall survival was constructed. We performed the consistency index (C-index) test and decision curve analysis (DCA) on the nomogram, and used gene set enrichment analysis (GSEA) to identify the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway of model genes. We selected PRMG based on the expression of metabolic genes, and used LASSO Cox regression to construct 16 metabolic gene models (SEPHS1, P4HA1, ENPP2, PTGDS, GPX3, CP, ASPA, POLR3A, PKM, POLR2D , XDH, EPHX2, ADH1B, HMGCL, GPD1L and MAOA). RESULTS: The risk score generated from our model can well predict the survival prognosis of COAD. A nomogram based on the clinicopathological characteristics and risk scores of COAD can personally predict the overall survival rate of COAD patients. CONCLUSIONS: The risk score based on the expression of 16 metabolic genes can effectively predict the prognosis of patients with COAD.
RNF38 enhances 5-Fluorouracil resistance in colorectal cancer by activating the Wnt pathway.
Long Y, Zhao Q, Huang Y
J BUON · 2021 · PMID 34564977
PURPOSE: Colorectal cancer (CRC) is a frequent fatal cancer worldwide. 5-Fluorouracil (5-FU) is extensively used in its chemotherapy. This drug resistance, however, should be well concerned. Ring finger proteins (RNF) ar...
PURPOSE: Colorectal cancer (CRC) is a frequent fatal cancer worldwide. 5-Fluorouracil (5-FU) is extensively used in its chemotherapy. This drug resistance, however, should be well concerned. Ring finger proteins (RNF) are vital regulators involved in CRC development. In this article, HCT116R cells were first established. The roles of RNF38 and Wnt signaling in 5-FU-resistant CRC were further illustrated. Our study provides novel evidence for improving 5-FU chemotherapy outcome in CRC patients. METHODS: The phenotype of established HCT116R cells was first examined. Next, the regulatory effect of RNF38 on 5-FU resistance in CRC was mainly explored. Nude mice bearing CRC were treated with 5-FU and in vivo overexpression of RNF38. RESULTS: 5-FU-resistant HCT-116 cells (HCT116R) were first established. 5-FU treatment markedly killed survival and induced apoptosis in HCT-116 cells. P53 was downregulated in HCT116R cells. Through microarray analysis, RNF38 was found to be upregulated in HCT116R cells compared to parental cells. CONCLUSIONS: Overexpression of RNF38 enhanced 5-FU resistance in CRC. Furthermore, Wnt signaling was activated by RNF38 and involved in 5-FU resistance in CRC.
Highly sensitive fecal DNA testing of NDRG4 12b methylation is a promising marker for detection of colorectal precancerosis.
Ji X, Sha J, Qian H … +3 more , Zhang G, He T, Dang Y
J BUON · 2021 · PMID 34564976
PURPOSE: The purpose of this study was to research and validate techniques for extracting DNA from human genomes, explore the sensitivity and specificity of known nucleic acid markers of intestinal malignancy in Chinese...
PURPOSE: The purpose of this study was to research and validate techniques for extracting DNA from human genomes, explore the sensitivity and specificity of known nucleic acid markers of intestinal malignancy in Chinese patients with early colorectal cancer. We also tried to find adenoma-specific biomarkers in human DNA in feces. METHODS: We compared the ability of fecal DNA testing, Fecal Occult Blood Testing (FOBT) and serum tumor markers to diagnose different types of polyps, and DNA testing was significantly superior to the other two methods. We also found a dominant expression of NDRG12b methylation in multi-target DNA testing, which may be a promising marker for detection of colorectal precancerosis. RESULTS: The sensitivity of NDRG4 12b methylation was 85.7% for advanced adenomatous polyp (AP), and 62.6% for non-advanced AP, respectively, with specificity of 70.8%. The diagnostic efficacy of NDRG4 12b methylation for detecting advanced AP was significantly higher than FOBT (sesitivity: 85.7% vs. 42.9%, p<0.05). The receiver operating characteristics (ROC) curve for NDRG4 12b methylation in detecting AP showed a relatively high area under the curve (AUC = 0.807). CONCLUSIONS: Our results indicate that highly sensitive fecal DNA testing of NDRG4 12b methylation is a promising marker for detection of colorectal precancerosis, especially in detecting adenomatous polyp.
A comparison of dosimetric and clinical parameters between different IMRT boost techniques in preoperative rectal cancer.
Karaca S, Aysenur Arli Karacam K
J BUON · 2021 · PMID 34564975
PURPOSE: In this study we compared the clinical and dosimetric outcomes of simultaneous integrated boost intensity modulated radiation therapy (SIB-IMRT) and sequential boost (SEQ-IMRT) techniques in preoperative rectal...
PURPOSE: In this study we compared the clinical and dosimetric outcomes of simultaneous integrated boost intensity modulated radiation therapy (SIB-IMRT) and sequential boost (SEQ-IMRT) techniques in preoperative rectal cancer (RC). METHODS: We analyzed 67 preoperative RC patients who received RT with Helical TomoTherapy (HT) device. 27 of patients were irradiated with SEQ-IMRT and 40 were irradiated with SIB-IMRT technique. The primary tumor and involved lymph nodes were simultaneously treated using the SIB-IMRT (50.4Gy/25 fraction). SEQ-IMRT delivered 45Gy/25 fractions to primary tumor (involved lymph nodes) and 5.4Gy/3fractions to boost volume. Dosimetric parameters, acute toxicities and 5year overal survival (OS), disease-free survival (DFS) and local control (LC) between two techniques were compared. RESULTS: In the SIB-IMRT group planning treatment volume (PTV) homogeneity index (HI) was better than in the SEQ-IMRT group. PTV doses of Dmax for SEQ-IMRT group were higher than the SIB-IMRT group (p<0.05). The bladder doses of Dmax in the SIB-IMRT group were higher than SEQ-IMRT group (p<0.005). There were no significant differences in other dosimetric parameters between groups. Median follow up was 29.06 months (range 4.3-92.07) and 36.46 months (range 8.7-79.6) in the SIB-IMRT and SEQ-IMRT groups, respectively. No significant difference was found between the SIB-IMRT and SEQ-IMRT groups in acute toxicity (p=0,909). Five-year OS, DFS and LC were 73.15%, 66.75% and 75.55% in SIB-IMRT group and 65.19%, 55.53% and 60.22% in the SEQ-IMRT group, respectively. No statically significant differences were found between the two groups regarding 5-year OS, DFS and LC. CONCLUSIONS: SIB-IMRT and SEQ-IMRT tecniques provided similar outcomes for dosimetric and clinical results for RC in HT treatment.
Diagnostic value of combined detection of multiple tumor markers and blood lipid indexes in colorectal cancer and its prediction on adverse reactions of chemotherapy.
Jiang M, Ding G, Li G
J BUON · 2021 · PMID 34564974
PURPOSE: The purpose of this study was to explore the clinical diagnostic value of combined detection of multiple tumor markers (CEA, CA242, CA19.9 and CA125) and blood lipid indexes in colorectal cancer, and to analyze...
PURPOSE: The purpose of this study was to explore the clinical diagnostic value of combined detection of multiple tumor markers (CEA, CA242, CA19.9 and CA125) and blood lipid indexes in colorectal cancer, and to analyze their predictive effect on adverse reactions after chemotherapy. METHODS: The clinical data of 35 patients with colorectal adenoma, 64 patients with colorectal cancer I-II and 29 patients with colorectal cancer III-IV were retrospectively analyzed. All the patients were admitted to our hospital from April 2017 to December 2019. The antigen level of tumor markers and the plasma level in patients were detected before surgery to compare the expression difference of different tumor types. The Youden index, sensitivity and specificity of the four tumor markers were compared when used alone or in combination. RESULTS: After one year of follow-up, the levels of tumor markers in patients with tumor metastasis were significantly higher than those in patients without tumor metastasis, with a statistically significant difference (p<0.001). The combination of four markers was better than single tumor marker in the evaluation indexes of diagnostic effect. The combined detection of multiple tumor markers and blood lipid indexes was correlated with the occurrence of five adverse reactions of chemotherapy (p<0.05). CONCLUSION: The detection of multiple tumor markers and blood lipid indexes can effectively improve the diagnosis of colorectal cancer and enhance the predictive effect on adverse reactions of chemotherapy. HDL, LDL and ApoAI indexes can be used to diagnose the benign and malignant properties of tumors, and determine the clinical stages.
Atorvastatin inhibits proliferation and promotes apoptosis of colon cancer cells via COX-2/PGE2/β-Catenin Pathway.
Cai S, Gao Z
J BUON · 2021 · PMID 34564973
PURPOSE: To explore the effects of atorvastatin (ATST) on the proliferation and apoptosis of colon cancer cells through the cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2)/β-catenin pathway. METHODS: HCT116 cells were c...
PURPOSE: To explore the effects of atorvastatin (ATST) on the proliferation and apoptosis of colon cancer cells through the cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2)/β-catenin pathway. METHODS: HCT116 cells were cultured and transfected, and they were treated with ATST at different concentrations for different time. The association between the expressions of COX-2 and PGE2 and the survival time of patients with colon cancer was analyzed via Kaplan-Meier survival analysis. Then the protein expressions of COX-2, β-catenin and apoptosis-related molecules in HCT116 cells were determined using Western blotting, and the proliferation of HCT116 cells was detected via cell counting kit-8 (CCK-8) assay. RESULTS: There was a significant difference in the survival rate between HCT116 cells treated with 30 μM ATST and those treated with 0 μM ATST. The survival time was obviously longer in patients with low expressions of COX-2 and PGE2 than that those with high expressions of COX-2 and PGE2. Low expressions of COX-2 and PGE2 in colon cancer tissues indicate a longer survival time. Moreover, a positive correlation was found between HCT116 cell density and COX-2 level, HCT116 cell density and PGE2 level, and COX-2 and PGE2 levels. ATST could down-regulate COX-2 and β-catenin, and knocking down COX-2 could lower β-catenin. After treatment with ATST and ATST + anti-COX-2, the activity of cleaved caspase-9, caspase-3 and PARP was remarkably enhanced, suggesting that ATST and ATST + anti-COX-2 can promote apoptosis of HCT116 cells. It was found that ATST and ATST + anti-COX-2 could also inhibit the proliferation of HCT116 cells.
Down regulation of tumour biomarkers in colon cancer cells with IRNA PFK-1 plus metformin.
Reyes Serratos EA, Fernandez Castillo E, Sanchez Lopez L … +6 more , Salinas Santander M, Orozco Nunnelly DA, Sanchez Salazar MG, Cervantes Astorga E, Rivas Estilla AM, Rios Ibarra CP
J BUON · 2021 · PMID 34564972
PURPOSE: Metformin has been widely used for the treatment of Type 2 Diabetes Mellitus (T2DM), hyperglycemia and polycystic ovarian syndrome. Recent studies have suggested the potential of this substance as a cancer chemo...
PURPOSE: Metformin has been widely used for the treatment of Type 2 Diabetes Mellitus (T2DM), hyperglycemia and polycystic ovarian syndrome. Recent studies have suggested the potential of this substance as a cancer chemopreventive agent. We evaluated the antitumoral effect of iRNA-PFK-1 and the combined therapy iRNA-PFK-1 + metformin in RKO p53-positive cells. METHODS: mRNA levels of tumor suppressor genes AMPK, APC, and c-MYC, KRAS oncogenes were measured by qRT-PCR in RKO cells treated with 25 µM metformin alone or combined with iRNA-PFK-1, to evaluate the effect of both treatments. RESULTS: At 72 h after treatment with either 25 µM metformin, 150 nM iRNA-PFK-1, or the combined treatment, the transcriptional levels of these biomarkers were decreased by ~73% (p˂0.05), ~99.9%, (p˂0.01), and ~76% (p˂0.05), respectively. CONCLUSION: These in vitro results support the potential therapeutic role of metformin and PFK-1 in the treatment of colon cancer via down-modulation of the expression of several important cancer biomarkers.
Liver transplantation for unresectable colorectal liver metastases.
Moris D
J BUON · 2021 · PMID 34564971
Abstract loading — click title to view on PubMed.
Oncologic outcomes after laparoscopic versus open resection for colorectal liver metastases.
Moris D
J BUON · 2021 · PMID 34564970
Abstract loading — click title to view on PubMed.
Classification, histopathology and molecular pathology of thymic epithelial tumors: a review.
Valavanis C, Stanc GM, Baltayiannis N
J BUON · 2021 · PMID 34564969
Thymic epithelial tumors represent 0.2-1.5% among all malignant neoplasms. They are slow-growing tumors with an overall recurrence rate around 10% and 90% of them are located in the anterior mediastinum. In this review w...
Thymic epithelial tumors represent 0.2-1.5% among all malignant neoplasms. They are slow-growing tumors with an overall recurrence rate around 10% and 90% of them are located in the anterior mediastinum. In this review we focused on the classification, histopathology, molecular pathology and prognosis of thymic epithelial tumors, mainly thymoma and thymic carcinoma.
About
- Frequency
- Sun
- Papers found
- 200
- RSS feed
- Subscribe